Chinese biopharma developing monoclonal antibody drugs, including anti-infective antibody candidates; specifics not fully established.
Chinese biopharma developing monoclonal antibody drugs, including anti-infective antibody candidates; specifics not fully established.
Moat: none
Headquarters: Zhuhai, China · Employees: 843
Size Zhuhai Trinomab Pharmaceutical (688806.SS) is a China Health Care company (Biotechnology) with a market value of $1.32B, the 1710th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.54 on 18 Nov 2026.
Growth Revenue grew 237.6% over the last twelve months (peer median +13.0%); the operating margin is -1,195.9% (peer median -38.9%).
Valuation It trades at 164.8× enterprise value to sales against a peer median of 8.4× (5th most expensive of 19).
Capital Return on invested capital runs 110.8 points below its cost of capital (6.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | CN¥50.8M | CN¥15.1M | CN¥0 |
| Revenue growth | — | +238% | — | — |
| Gross profit | n/a | -CN¥11.9M | -CN¥55.1M | -CN¥62.3M |
| EBITDA | n/a | -CN¥554M | -CN¥460M | -CN¥406M |
| Net income | n/a | -CN¥601M | -CN¥515M | -CN¥446M |
| Free cash flow | n/a | -CN¥599M | -CN¥378M | -CN¥321M |
| Capital expenditure | n/a | CN¥22.4M | CN¥16.3M | CN¥20.9M |
| Total debt | CN¥875M | CN¥696M | CN¥402M | CN¥204M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688806.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.2% | -15.2% | 10th lowest of 21 |
| Distance from 52-week high | -62.8% | -46.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +237.6% | +13.0% | 3rd highest of 18 |
| Operating margin | -1,195.9% | -38.9% | 3rd lowest of 19 |
| EV / Sales | 164.8× | 8.4× | 5th most expensive of 19 |
| ROIC minus cost of capital | -110.8 pp | -6.9 pp | lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 6.8× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |